Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers February 15, 2019
Pharmacy Choice - Pharmaceutical News - Alnylam to Host Fifth Annual RNAi Roundtable Webcast Series - February 15, 2019

Pharmacy News Article

 6/21/18 - Alnylam to Host Fifth Annual RNAi Roundtable Webcast Series

CAMBRIDGE, Mass.(BUSINESS WIRE) Alnylam Pharmaceuticals, Inc.(Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 5th annual series of RNAi Roundtable webcasts this summer. The 2018 series will offer a range of presentations from Alnylam scientists, clinical collaborators, and patients or patient advocates, who will review recent progress in many of the Company's late-stage pipeline programs and platform. Each event will be webcast live on the Investors page of the Company's website,, and a replay of the roundtables will be posted on the Alnylam website approximately three hours after each event.

The 2018 RNAi Roundtable schedule will be as follows:

  • Platform Advances in RNAi Therapeutics
    Tuesday, June 26, 10:30 am ET
  • Givosiran, in Development for the Treatment of Acute Hepatic Porphyrias
    Tuesday, July 24, 10:00 am ET
  • Lumasiran, in Development for the Treatment of Primary Hyperoxaluria Type 1
    Wednesday, August 15, 10:30 am ET
  • Patisiran & ALN-TTRsc02, for the Treatment of Transthyretin-Mediated Amyloidosis
    Tuesday, September 11, time TBD

Please visit the Capella section of our website for the latest information regarding webcast schedules.

About RNAi
RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as a major scientific breakthrough that happens once every decade or so, and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a major new class of medicines, known as RNAi therapeutics, is on the horizon. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, function upstream of today's medicines by potently silencing messenger RNA (mRNA) the genetic precursors that encode for disease-causing proteins, thus preventing them from being made. This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases.

About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, and hepatic infectious diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust discovery platform and deep pipeline of investigational medicines, including four product candidates that are in late-stage development. Looking forward, Alnylam will continue to execute on its "Alnylam 2020" strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines to address the needs of patients who have limited or inadequate treatment options. Alnylam employs over 800 people in the U.S. and Europe and is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please and engage with us on Twitter at @Alnylam or on LinkedIn.

Alnylam Pharmaceuticals, Inc.

Christine Regan Lindenboom, 617-682-4340

(Investors and Media)


Josh Brodsky, 617-551-8276


Source: Alnylam Pharmaceuticals, Inc.

Copyright Business Wire 2018

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Feb 18: Management of Schizophrenia & Acute Agitation
Feb 19: Treatment of Atopic Dermatitis (Eczema) & Xerosis (Dry Skin)
Feb 20: Know Your Value, Know Your Worth: Provider Status in Pharmacy
Feb 21: Type II Diabetes: Case Studies and Management Options
Feb 22: Medical Marijuana: The Basic and Clinical Pharmacology, Not The Politics
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2019 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement